$GNLX News
Last published 2mo ago
- 2mo agoGNLXGenelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed ImmunochemotherapyGlobeNewswire-- A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy -- -- This
- 3mo agoGNLXGenelux Corporation Reports Second Quarter Financial Results and Provides Business UpdatesGlobeNewswire-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Olvi-Vec systemic development programs continue to advance, with additional dose-escalation updates
- 3mo agoMBXARQTNAMSGNLXAttovia Therapeutics Appoints John W. Smither to Board of DirectorsGlobeNewswireSAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for
- 4mo agoGNLXGenelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian CancerGlobeNewswire- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial - - Data demonstrate Olvi-Vec–mediated modulation
- 6mo agoGNLXGenelux Corporation Reports First Quarter Financial Results and Provides Business UpdatesGlobeNewswire-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer programs advancing with additional updates expected throughout 2026 --
- 8mo agoGNLXGenelux Corporation to Participate in Upcoming ConferencesGlobeNewswireWESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in two upcoming
- 10mo agoGNLXGenelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan PartnersGlobeNewswireWESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the
- 10mo agoGNLXGenelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common StockGlobeNewswireWESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation ("Genelux") (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten public offering
- 10mo agoGNLXGenelux Corporation Announces Proposed Public Offering of Common StockGlobeNewswireWESTLAKE VILLAGE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation ("Genelux") (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a proposed underwritten
- 10mo agoGNLXGenelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer TrialsGlobeNewswire-- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment ongoing – -- In
- 10mo agoGNLXGenelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical OfficerGlobeNewswireWESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical
- 11mo agoGNLXGenelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireWESTLAKE VILLAGE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the
- 1y agoGNLXGenelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business UpdatesGlobeNewswire-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 -- -- Cash, cash
- 1y agoGNLXGenelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment ConferenceGlobeNewswireWESTLAKE VILLAGE, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the
- 1y agoGNLXGenelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business UpdatesGlobeNewswireWESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and
- 1y agoGNLXGenelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business DevelopmentGlobeNewswireWESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel,
- 1y agoGNLXGenelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business UpdatesGlobeNewswireWESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2025 and provided
- 1y agoGNLXGenelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences ConferenceGlobeNewswireWESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the
- 1y agoGNLXGenelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswire– Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer – – Positive Preliminary Phase 1b/2 Data of Olvi-Vec in
- 1y agoGNLXGenelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common StockGlobeNewswireWESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation ("Genelux") (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of
- 1y agoGNLXGenelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung CancerGlobeNewswire– Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a reduction in all
- 1y agoGNLXGenelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory DiseaseGlobeNewswire- U.S. Food and Drug Administration states that data from the ongoing OnPrime/GOG-3076 Phase 3 registrational trial could potentially support traditional approval - WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE
- 1y agoGNLXGenelux Corporation Announces New Chief Financial OfficerGlobeNewswireWESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new
- 1y agoGNLXGenelux Corporation to Participate in a Fireside Chat with H.C. WainwrightGlobeNewswireWESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the
- 1y agoGNLXNAMSFrazier Life Sciences Appoints John Smither and Jim Williams as Senior AdvisorsBusiness WireFrazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the addition of industry veterans John Smither and Jim Williams, MBA, as Senior Advisors. "John and Jim
- 1y agoGNLXGenelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business UpdatesGlobeNewswireWESTLAKE VILLAGE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2024 and provided
- 2y agoGNLXGenelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung CancerGlobeNewswire– VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent non-small cell
- 2y agoGNLXGenelux Corporation to Participate in the 2024 Maxim Healthcare Virtual SummitGlobeNewswireWESTLAKE VILLAGE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the
- 2y agoGNLXGenelux Corporation to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireWESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, Chairman and CEO, will
- 2y agoGNLXGenelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business UpdatesGlobeNewswireWESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2024 and
- 2y agoGNLXGenelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024GlobeNewswireWESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman, will
- 2y agoGNLXGenelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying WarrantsGlobeNewswireWESTLAKE VILLAGE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of
- 2y agoGNLXGenelux Corporation Announces Proposed Public Offering of Common Stock and WarrantsGlobeNewswireWESTLAKE VILLAGE, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced an underwritten public
- 2y agoGNLXGenelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business UpdatesGlobeNewswireWESTLAKE VILLAGE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2024 and provided
- 2y agoGNLXGenelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian CancerGlobeNewswire- Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 - - Phase 2 Trial of Olvi-Vec- Demonstrated Clinical Reversal of Platinum Resistance and Refractoriness and
- 2y agoGNLXGenelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business UpdatesGlobeNewswire- Expanded executive team as Lourie Zak appointed Chief Financial Officer - - Extended clinical focus on systemic administration in small cell lung cancer - - $29.9 million in cash and equivalents - WESTLAKE VILLAGE,
- 3y agoCRNXGNLXONCYPFE+1Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future TreatmentPR NewswireFN Media Group Presents USA News Group News Commentary VANCOUVER, British Columbia, Oct. 11, 2023 /PRNewswire/ -- USA News Group - Researchers are becoming increasingly concerned with the rates of cancer on the rise
- 3y agoGNLXGenelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the Company's Board of
- 3y agoGNLXGenelux Corporation to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireWESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, Chairman and CEO, will
- 3y agoGNLXGenelux Corporation Announces New Chief Financial OfficerGlobeNewswireWESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the company as Chief Financial
- 3y agoGNLXGenelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business UpdatesGlobeNewswire- Inclusion into the broad-market Russell 3000® Index and small-cap Russell 2000® Index - - Publication of VIRO-15 Phase 2 data in JAMA Oncology - - $51 Million raised after closing of two private
- 3y agoGNLXGenelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New HiresGlobeNewswireWESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as well as the addition of
- 3y agoGNLXGenelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in ImmunologyGlobeNewswirePhase 1 trial conducted at Memorial Sloan Kettering Cancer Center, New York, investigated the safety, feasibility and immune activating effects of Olvi-Vec by intrapleural administration. Documented Olvi-Vec infection of
- 3y agoGNLXGenelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLCGlobeNewswire- V2ACT Therapeutics™, LLC is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. - V2ACT Immunotherapy is a proprietary immuno-oncology modality composed of Olvi-Vec (oncolytic viral
- 3y agoGNLXGenelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023GlobeNewswireWESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad-market Russell 3000®
- 3y agoGNLXGenelux Corporation Announces $18 Million Private PlacementGlobeNewswireWESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares of the Company's
- 3y agoGNLXGenelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) OncologyGlobeNewswirePhase 2 Trial of Olvi-Vec-primed immunochemotherapy in heavily pre-treated patients Met primary endpoint of objective response rate with deep and durable responsesGenerated promising progression-free
- 3y agoGNLXGenelux Corporation Announces $33 Million Private PlacementGlobeNewswireWESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares of the Company's
- 3y agoGNLXGenelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023GlobeNewswireWESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX) ("Genelux" or "the Company"), a late clinical-stage biopharmaceutical company focused on developing a pipeline of
- 3y agoGNLXGenelux Corporation Announces Pricing of Initial Public OfferingGlobeNewswireWESTLAKE VILLAGE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation ("Genelux" or "the Company"), a clinical-stage immunotherapy company focused on developing a pipeline of next-generation oncolytic viral